Aralast™ is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA, since they may experience severe reactions, including anaphylaxis, to IgA which may be present.
Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 1988 (Suppl 6A);84:13-31.
Data on file at Alpha Therapeutic Corporation.
Crystal RG, Brantly ML, Hubbard RC, Curiel DT, et al. The alpha1-antitrypsin gene and its mutations: Clinical consequences and strategies for therapy. Chest 1989;95:196-208.
Crystal RG. (alpha)1-Antitrypsin deficiency: pathogenesis and treatment. Hospital Practice 1991; Feb.15:81-94.
Hutchison DCS. Natural history of alpha-1-protease inhibitor deficiency. Am J Med 1988;84(Suppl 6A):3-12.
Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988;84(Suppl 6A):52-62.
Ogushi F, Fells GA, Hubbard RC, et al. Z-Type (alpha)1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Investigation 1987;80:1366-1374.
Buist SA, Burrows B, Cohen A, et al. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1989;140:1494-1497.
Stoller JK, Brantly M, Fleming LE, et al. Formation and current results of a patient-organized registry for (alpha)1-antitrypsin deficiency. Chest 2000; 118(3):843-848.
DATE OF REVISION: January 2003
LOS ANGELES, CA 90032 USA
U.S. LICENSE NO. 744
Baxter Healthcare Corporation
One Baxter Way
Westlake Village, CA 91362 USA
© 2002 Alpha Therapeutic Corporation
Printed In USA